<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-1535625-B1" country="EP" doc-number="1535625" kind="B1" date="20140108" family-id="34468505" file-reference-id="287008" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146589171" ucid="EP-1535625-B1"><document-id><country>EP</country><doc-number>1535625</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-05001956-A" is-representative="YES"><document-id mxw-id="PAPP154851363" load-source="docdb" format="epo"><country>EP</country><doc-number>05001956</doc-number><kind>A</kind><date>20000405</date><lang>EN</lang></document-id><document-id mxw-id="PAPP246818699" load-source="docdb" format="original"><country>EP</country><doc-number>05001956.1</doc-number><date>20000405</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140554979" ucid="EP-00921909-A" linkage-type="3" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>00921909</doc-number><kind>A</kind><date>20000405</date></document-id></priority-claim><priority-claim mxw-id="PPC140547642" ucid="US-12775499-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>12775499</doc-number><kind>P</kind><date>19990405</date></document-id></priority-claim><priority-claim mxw-id="PPC140553961" ucid="US-18614200-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>18614200</doc-number><kind>P</kind><date>20000301</date></document-id></priority-claim><priority-claim mxw-id="PPC140547413" ucid="US-18614300-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>18614300</doc-number><kind>P</kind><date>20000301</date></document-id></priority-claim><priority-claim mxw-id="PPC140548309" ucid="US-19128600-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>19128600</doc-number><kind>P</kind><date>20000321</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130719</date></intention-to-grant-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989327816" load-source="docdb">A61K  38/23        20060101AFI20130604BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989631358" load-source="docdb">C07D 265/26        20060101A I20051008RMEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1989620469" load-source="docdb" scheme="CPC">A61K   9/2054      20130101 FI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989632487" load-source="docdb" scheme="CPC">C07D 265/26        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989637516" load-source="docdb" scheme="CPC">A61K   9/19        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989637883" load-source="docdb" scheme="CPC">A61K   9/48        20130101 LI20130101BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132372146" lang="DE" load-source="patent-office">Zubereitung enthaltend n-(5-chlorosalicyloyl)-8-Aminocapronsäure und Lachscalcitonin</invention-title><invention-title mxw-id="PT132372147" lang="EN" load-source="patent-office">Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin</invention-title><invention-title mxw-id="PT132372148" lang="FR" load-source="patent-office">Composition contenant de n-(5-chlorosalicyloyl)-8-amino-acide caproique et calcitonine de saumon</invention-title></technical-data><related-documents><relation type="division"><child-doc ucid="EP-05001956-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>05001956</doc-number><kind>A</kind><date>20000405</date></document-id></child-doc><parent-doc ucid="EP-00921909.8"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>00921909.8</doc-number><date>20000405</date></document-id></parent-doc></relation></related-documents><parties><applicants><applicant mxw-id="PPAR919537500" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>NOVARTIS AG</last-name><address><country>CH</country></address></addressbook></applicant><applicant mxw-id="PPAR919528779" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>NOVARTIS AG</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919527925" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>AZRIA MOISE</last-name><address><country>CH</country></address></addressbook></inventor><inventor mxw-id="PPAR919522050" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>AZRIA, MOISE</last-name></addressbook></inventor><inventor mxw-id="PPAR919026677" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>AZRIA, MOISE</last-name><address><street>Bundesplatz 6</street><city>4054 Basel</city><country>CH</country></address></addressbook></inventor><inventor mxw-id="PPAR919509204" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>AULT JOSEPH MURRAY</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919514738" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>AULT, JOSEPH MURRAY</last-name></addressbook></inventor><inventor mxw-id="PPAR919026680" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>AULT, JOSEPH MURRAY</last-name><address><street>4 Wards Road</street><city>Blairstown, NJ 07825</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919524826" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>BATEMAN SIMON DAVID</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919544545" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>BATEMAN, SIMON DAVID</last-name></addressbook></inventor><inventor mxw-id="PPAR919026679" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>BATEMAN, SIMON DAVID</last-name><address><street>4 Farington Lane</street><city>Randolph, NJ 07869</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919529779" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>PATEL SUBASH</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919503800" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>PATEL, SUBASH</last-name></addressbook></inventor><inventor mxw-id="PPAR919026681" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>PATEL, SUBASH</last-name><address><street>76 East Cliff Street, Apt. 7</street><city>Somerville, NJ 08876</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919541914" load-source="docdb" sequence="5" format="epo"><addressbook><last-name>SIKORA JOSEPH</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919534805" load-source="docdb" sequence="5" format="intermediate"><addressbook><last-name>SIKORA, JOSEPH</last-name></addressbook></inventor><inventor mxw-id="PPAR919026678" load-source="patent-office" sequence="5" format="original"><addressbook><last-name>SIKORA, JOSEPH</last-name><address><street>16 Toby Drive</street><city>Succasunna, NJ 07876</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919512474" load-source="docdb" sequence="6" format="epo"><addressbook><last-name>YANG REBECCA FAI-YING</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919507452" load-source="docdb" sequence="6" format="intermediate"><addressbook><last-name>YANG, REBECCA FAI-YING</last-name></addressbook></inventor><inventor mxw-id="PPAR919026683" load-source="patent-office" sequence="6" format="original"><addressbook><last-name>YANG, REBECCA FAI-YING</last-name><address><street>7 Hawser Way</street><city>Randolph, NJ 07869</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919508480" load-source="docdb" sequence="7" format="epo"><addressbook><last-name>ZIELINSKI JOSEPH L</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919506082" load-source="docdb" sequence="7" format="intermediate"><addressbook><last-name>ZIELINSKI, JOSEPH L.</last-name></addressbook></inventor><inventor mxw-id="PPAR919026682" load-source="patent-office" sequence="7" format="original"><addressbook><last-name>ZIELINSKI, JOSEPH L.</last-name><address><street>53 Beechwood Road</street><city>Florham Park, NJ 07932</city><country>US</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919026685" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Novartis AG</last-name><iid>100189475</iid><address><street>Lichtstrasse 35</street><city>4056 Basel</city><country>CH</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919026684" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Grünecker, Kinkeldey, Stockmair &amp; Schwanhäusser Anwaltssozietät</last-name><iid>100060488</iid><address><street>Leopoldstrasse 4</street><city>80802 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><designated-states><ep-contracting-states><country mxw-id="DS549794024" load-source="docdb">AT</country><country mxw-id="DS549884593" load-source="docdb">BE</country><country mxw-id="DS549899824" load-source="docdb">CH</country><country mxw-id="DS549791476" load-source="docdb">CY</country><country mxw-id="DS549884598" load-source="docdb">DE</country><country mxw-id="DS549791481" load-source="docdb">DK</country><country mxw-id="DS549807308" load-source="docdb">ES</country><country mxw-id="DS549891018" load-source="docdb">FI</country><country mxw-id="DS549891019" load-source="docdb">FR</country><country mxw-id="DS549884599" load-source="docdb">GB</country><country mxw-id="DS549791482" load-source="docdb">GR</country><country mxw-id="DS549899829" load-source="docdb">IE</country><country mxw-id="DS549891020" load-source="docdb">IT</country><country mxw-id="DS549791483" load-source="docdb">LI</country><country mxw-id="DS549794033" load-source="docdb">LU</country><country mxw-id="DS549875795" load-source="docdb">MC</country><country mxw-id="DS549807309" load-source="docdb">NL</country><country mxw-id="DS549899830" load-source="docdb">PT</country><country mxw-id="DS549807310" load-source="docdb">SE</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><description mxw-id="PDES63961583" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b><u>BACKGROUND OF THE INVENTION</u></b></heading><p id="p0001" num="0001"><patcit id="pcit0001" dnum="US5773647A"><text>U.S. Patent Nos. 5,773,647</text></patcit> and <patcit id="pcit0002" dnum="US5866536A"><text>5,866,536</text></patcit> disclose compositions for the oral delivery of active agents, such as heparin and calcitonin, with modified amino acids, such as <i>N</i>-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), <i>N</i>-(10-[2-hydroxybenzoyl]amino)decanoic acid (SNAD), and <i>N</i>-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC). Many current commercial formulations containing an active agent, such as heparin and calcitonin, are delivered by routes other than the oral route. Formulations<!-- EPO <DP n="2"> --> delivered orally are typically easier to administer than by other routes and improve patient compliance.</p><p id="p0002" num="0002">There is a need for improved pharmaceutical formulations for orally administering a calcitonin.</p><heading id="h0002"><b><u>SUMMARY OF THE INVENTION</u></b></heading><p id="p0003" num="0003">Accordingly the present invention provides the subject method of claim 1.<!-- EPO <DP n="3"> --></p><heading id="h0003"><b><u>DETAILED DESCRIPTION OF THE INVENTION</u></b></heading><heading id="h0004"><u>Disodium Salt</u></heading><p id="p0004" num="0004">The disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid may be prepared from the ethanol solvate by evaporating or drying the ethanol by methods known in the art to form the anhydrous disodium salt. Generally, drying is performed at a temperature of from about 80 to about 120, preferably from about 85 to about 90, and most preferably at about 85° C. Typically, the drying step is performed at a pressure of 26" Hg or greater. The anhydrous disodium salt generally contains less than about 5% by weight of ethanol and preferably less than about 2% by weight of ethanol, based upon 100% total weight of anhydrous disodium salt.</p><p id="p0005" num="0005">The disodium salt of the delivery agent may also be prepared by making a slurry of the delivery agent in water and adding two molar equivalents of aqueous sodium hydroxide, sodium alkoxide, or the like. Suitable sodium alkoxides include, but are not limited to, sodium methoxide, sodium ethoxide, and combinations thereof.</p><p id="p0006" num="0006">Yet another method of preparing the disodium salt is by reacting the delivery agent with one molar equivalent of sodium hydroxide to form a monosodium salt of the delivery agent and then adding an additional one molar equivalent of sodium hydroxide to yield the disodium salt.</p><p id="p0007" num="0007">The disodium salt can be isolated as a solid by concentrating the solution containing the disodium salt to a thick paste by vacuum distillation. This paste may be dried in a vacuum oven to obtain the disodium salt of the delivery agent as a solid. The solid can also be isolated by spray drying an aqueous solution of the disodium salt.</p><p id="p0008" num="0008">The delivery agent may be prepared by methods known in the art, such as those described in <patcit id="pcit0003" dnum="US5773647A"><text>U.S. Patent Nos. 5,773,647</text></patcit> and <patcit id="pcit0004" dnum="US5866536A"><text>5,866,536</text></patcit>, respectively.<!-- EPO <DP n="4"> --></p><p id="p0009" num="0009">Most preferably, the composition comprises substantially pure disodium salt of the delivery agent. The term "substantially pure" as used herein means that less than about 4% and preferably less than about 2% by weight of the delivery agent in the composition is not a disodium salt, based upon 100% total weight of the delivery agent and salts thereof in the composition.<!-- EPO <DP n="5"> --></p><heading id="h0005"><u>Disodium Salt, and Dosage Unit Forms</u></heading><p id="p0010" num="0010">The use as claimed also provides a composition, such as a pharmaceutical composition, comprising at least one of a disodium salt of the<!-- EPO <DP n="6"> --> present invention and at least one active agent. The composition typically contains a delivery effective amount of disodium salt, of the present invention, <i>i</i>.<i>e</i>., an amount of the disodium salt sufficient to deliver the active agent for the desired effect.<!-- EPO <DP n="7"> --></p><p id="p0011" num="0011">The amount of active agent in the composition is an amount effective to accomplish the purpose intended. The amount in the composition is typically a pharmacologically, biologically, therapeutically, or chemically effective amount. However, the amount can be less than that amount when a plurality of the compositions are to be administered, <i>i</i>.<i>e</i>., the total effective amount can be administered in cumulative units. The amount of active agent can also be more than a pharmacologically, biologically, therapeutically, or chemically effective amount when the composition provides sustained release of the active agent. Such a composition typically has a sustained release coating which causes the composition to release a pharmacologically, biologically, therapeutically, or chemically effective amount of the active agent over a prolonged period of time.</p><p id="p0012" num="0012">The total amount of active agent to be used can be determined by methods known to those skilled in the art. However, because the compositions may deliver the active agent more efficiently than prior compositions, lesser amounts of the active agent than those used in prior dosage unit forms or delivery systems can be administered to the subject, while still achieving the same blood levels and/or therapeutic effects.</p><p id="p0013" num="0013">According to one preferred embodiment, the composition comprises a disodium salt of the delivery agent and salmon calcitonin. The delivery agent is 5-CNAC. Generally, the weight ratio of salmon calcitonin to disodium salt of 5-CNAC varies depending on the animal to which the composition is to be administered. For example, for a composition which is to be administered to humans.the weight ratio may range from about 1:300 to about 1:700 and is preferably about 1 :500. For primates, the weight ratio generally ranges from about 1: 100 to about 1:500.</p><p id="p0014" num="0014">The composition may be in liquid or solid form. Preferably, compositions containing the disodium salt are in solid form. The composition may further comprise additives including, but not limited to, a pH adjuster, a preservative, a flavorant, a taste-masking agent, a fragrance, a humectant, a tonicifier, a colorant, a surfactant, a plasticizer, a lubricant, a dosing vehicle, a solubilizer, an excipient, a diluent, a disintegrant, or any combination of any of the foregoing. Suitable dosing vehicles include, but are not limited to, water, phosphate buffer, 1,2-propane diol, ethanol, olive oil, 25% aqueous propylene glycol, and any combination of any of the foregoing. Other additives include phosphate buffer salts, citric acid, glycols, and other<!-- EPO <DP n="8"> --> dispersing agents. Stabilizing additives may be incorporated into the solution, preferably at a concentration ranging between about 0.1 and 20% (w/v).</p><p id="p0015" num="0015">The composition may also include one or more enzyme inhibitors, such as actinonin or epiactinonin and derivatives thereof. Other enzyme inhibitors include, but are not limited to, aprotinin (Trasylol) and Bowman-Birk inhibitor.</p><p id="p0016" num="0016">The composition may be prepared by dry mixing or mixing in solution the disodium salt, active agent, and, optionally, additives. The mixture may be gently heated and/or inverted to aid in dispersing the components in solution.</p><p id="p0017" num="0017">The composition may be formulated into a dosage unit form and in particular an oral dosage unit form, including, but not limited to, capsules, tablets, and particles, such as powders and sachets, by methods known in the art.</p><p id="p0018" num="0018">According to one preferred embodiment, the dosage unit form is a solid dosage unit form comprising a lyophilized mixture of the disodium salt of the present invention and at least one active agent.</p><p id="p0019" num="0019">The term "lyophilized mixture" includes, but is not limited to, mixtures prepared in dry form by rapid freezing and dehydration. Typically dehydration is performed while the mixture is frozen and under a vacuum. Lyophilized mixtures generally are substantially free of water and preferably contain less than 4% by weight of water, based upon 100% total weight of the mixture.</p><p id="p0020" num="0020">Such a solid dosage unit form may be prepared by (a) obtaining a solution comprising one or more delivery agents and one or more active agents, (b) lyophilizing the solution to obtain a lyophilized mixture, and (c) preparing a solid dosage unit form with the lyophilized mixture.</p><p id="p0021" num="0021">The delivery agent and active agent may be mixed in solution to form the solution in step (a). The solution may be lyophilized by any method known in the art. The lyophilized mixture may be incorporated into a dosage unit form by any method known in the art.</p><p id="p0022" num="0022">The composition and the dosage unit form of the present invention may be administered to deliver an active agent to any animal in need thereof including, but not limited to, birds, such as chickens; mammals, such as rodents, cows, pigs, dogs, cats, primates, and particularly humans; and insects. The composition and dosage unit form is for oral administration.<!-- EPO <DP n="9"> --></p><p id="p0023" num="0023">The following examples are intended to describe the present invention.</p><heading id="h0006"><u>Example 1</u></heading><heading id="h0007"><u>Preparation of N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC)</u></heading><p id="p0024" num="0024">To a clean, dry, 757,1ℓ (200 gallon) glass-lined reactor, 178 L of dry acetonitrile was added. The agi tator was set to 100-125 rpm and the reactor contents were cooled to about 9° C. 74 kg of 5-chloro salicylamide, available from Polycarbon Industries of Leominster, MA, was charged to the reactor and the charging port was closed. 47 L of dry pyridine was charged to the reactor. The resulting slurry was cooled to about 9° C. Cooling was applied to the reactor condenser and valve overheads were set for total reflux. Over 2 hours, 49.7 kg of ethylchloroformate was charged to the 757,1ℓ (200 gallon) reactor while maintaining the batch temperature at about 14° C. Ethylchloroformatecan contain 0.1% phosgene and is extremely reactive with water. The reaction is highly exothermic and requires the use of a process chiller to moderate reaction temperature.</p><p id="p0025" num="0025">The reactor contents were agitated for about 30 minutes at 10-14° C, once the ethylchloroformate addition was complete. The reactor contents were then heated to about 85° C over about 25 minutes, collecting all distillate into a receiver. The reactor contents were held at 85-94° C for approximately 6 hours, collecting all distilled material into a receiver. The reaction mixture was sampled and the conversion (&gt;90%) monitored by HPLC. The conversion was found to be 99.9% after 6 hours. The reactor contents were cooled to about 19° C over a one-hour period. 134 L of deionized water was charged to the reactor. A precipitate formed immediately. The reactor contents were cooled to about 5° C and agitated for about 10.5 hours. The product continued to crystallize out of solution. The reactor slurry was centrifuged. 55 L of deionized water was charged to the 757,1ℓ (200-gallon), glass-lined reactor and the centri fuge wet cake was washed. The intermediate was dried under full vacuum 948.2 HPa (28" Hg) at about 58° C for about 19.5 hours. The yield was 82.6 kg 6-chloro-2H-1,3-benzoxazine-2,4(3H)-dione.<!-- EPO <DP n="10"> --> This intermediate was packaged and stored so that it was not exposed to water.</p><p id="p0026" num="0026">In the following preparation, absolutely no water can be tolerated in the steps up to the point where distilled water is added. 222 L of dry dimethylacetamide was charged to a dry 757,1ℓ (200 gallon) glass-lined reactor. The reactor agitator was set to 100-125 rpm. Cooling was applied to the condenser and valve reactor overheads were set for distillation. 41.6 kg of dry anhydrous sodium carbonate was charged to the reactor and the reactor charging port was closed. Caution was used due to some off-gassing and a slight exothermic reaction. 77.5 kg of dry 6-chloro-2H-1,3-benzoxazine-2,4(3H)-dione was charged to the reactor. Quickly, 88 kg of dry ethyl-8-bromooctanoate was charged to the reactor. The reaction was evacuated to 745.0-812.7 HPa (22-24 inches) of vacuum and the reactor temperature was raised to 65-75° C. The reactor temperature was maintained and the contents were watched for foaming. The reactor mixture was sampled and monitored for conversion by monitoring the disappearance of the bromo ester in the reaction mixture by gas chromatography. The reaction was complete (0.6% bromo ester was found) after about 7 hours. The vacuum was broken and the reactor contents were cooled to 45-50° C. The contents were centrifuged and the filtrate sent into a second 757,1ℓ (200 gallon) glass-lined reactor. 119 L of ethanol (200 proof denatured with 0.5% toluene) was charged to the first 757,1ℓ (200 gallon) reactor, warmed to about 45° C. The filter cake was washed with warm ethanol and the wash was charged to the reaction mixture in the second 757,1ℓ (200 gallon) reactor.</p><p id="p0027" num="0027">The agitator was started on the second 757,1ℓ (200 gallon) reactor. The reactor contents were cooled to about 29° C. 120 L distilled water was slowly charged to the second reactor, with the water falling directly into the batch. The reactor contents were cooled to about 8° C. The intermediate came out of solution and was held for about 9.5 hours. The resultant slurry was centrifuged. 70 L ethanol was charged to the reactor, cooled to about 8° C, and the centrifuge cake was washed. The wet cake was unloaded into double polyethylene bags placed inside a paper lined drum. The yield was 123.5 kg of ethyl 8-(6-chloro-2H-1,3-benzoxazine-2,4(3H)-dionyl)octanoate.</p><p id="p0028" num="0028">400 L purified water, USP and 45.4 kg sodium hydroxide pellets were charged to a 757,1ℓ (200 gallon) glass-lined reactor and the agitator was set to 100-125 rpm. 123.5 kg of the ethyl 8-(6-chloro-2H-1,3-benzoxazine-2,4(3H)-dionyl)octanoate wet cake was charged to the reactor. The charging port was closed. Cooling water was applied to the condenser and the<!-- EPO <DP n="11"> --> valve reactor overheads were set for atmospheric distillation. The reactor contents were heated to about 98° C and the conversion was monitored by HLPC. Initially (approximately 40 minutes) the reactor refluxed at about 68° C, however, as the ethanol was removed (over about 3 hours) by distillation the reactor temperature rose to about 98° C. The starting material disappeared, as determined by HPLC, at approximately 4 hours. The reactor contents were cooled to about 27° C. 150 L purified water, USP was charged to an adjacent 757,1ℓ (200 gallon) glass-lined reactor and the agitator was set to 100-125 rpm. 104 L concentrated (12M) hydrochloric acid was charged to the reactor and cooled to about 24° C. The saponified reaction mixture was slowly charged (over about 5 hours) to the 757,1ℓ (200 gallon) glass-lined reactor. The material (45 L and 45 L) was split into 2 reactors (757,1ℓ (200 gallons) each) because of carbon dioxide evolution. The product precipitated out of solution. The reaction mixture was adjusted to pH 2.0-4.0 with a 50% sodium hydroxide solution (2L water, 2 kg sodium hydroxide). The reactor contents were cooled to about 9-15° C. The intermediate crystallized out of solution over approximately 9 hours. The reactor slurry was centrifuged to isolate the intermediate. 50 L purified water, USP was charged to a 757,1ℓ (200 gallon) glass-lined reactor and this rinse was used to wash the centrifuge wet cake. The wet cake was unloaded into double polyethylene bags plac d in ide a plastic drum. The <i>N</i>-(5-chlorosalicyloyl)-8-aminocaprylic acid was dried under vacuum 914.3 HPa (27" Hg) at about 68° C for about 38 hours. The dry cake was unloaded into double polyethylene bags placed inside a 208,2ℓ (55-gallon), steel unlined, open-head drums with a desiccant bag placed on top. The dried isolated yield was 81 kg of <i>N</i>-(5-chlorosalicyloyl)-8-aminocaprylic acid.<!-- EPO <DP n="12"> --></p><heading id="h0008"><u>Example 2</u></heading><heading id="h0009"><u>Preparation of Disodium <i>N</i>-(S-chlorosalicyloyl)-8-aminocaprylate</u></heading><p id="p0029" num="0029"><chemistry id="chem0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="155" he="61" img-content="chem" img-format="tif"/></chemistry></p><p id="p0030" num="0030">A 22 L, Pyrex glass, five-neck, round bottom flask was equipped with an overhead stirrer, thermocouple temperature read out, and heating mantle. The flask was charged with 2602.3 g of <i>N</i>-(5-chlorosalicyloyl)-8-aminocaprylic acid and 4000 mL water. To this stirred slurry was added a solution of 660 g of sodium hydroxide dissolved in 2000 mL water. The mixture was heated to about 55° C and most of the solids dissolved. The slightly hazy solution was hot filtered through Whatman #1 filter paper to remove the insoluble particulates. The filtrate was transferred to the pot flask of a large laboratory rotary evaporator. The rotary evaporator was operated with a bath temperature of about 60° C and a pressure of 60 mmHg. Water was removed from the disodium salt solution until a solid mass was obtained in the rotary evaporator pot flask. The vacuum was released and pot flask removed from the rotary evaporator. The solids were scraped from the pot flask into trays. These trays were then placed in a vacuum oven and the solids dried at about 60° C and full vacuum for about 48 hours. The dried solids were run through a laboratory mill until all the solids passed through a 35 mesh screen. The milled and sieved disodium <i>N</i>-(5-chlorosalicyloyl)-8-aminooctanate was put into trays and placed back into the drying oven. Drying was continued at about 45° C and full vacuum to obtain 2957.1 g of the desired product as a dry powder.</p><p id="p0031" num="0031">Titration of the product with hydrochloric acid gave two inflection points consuming approximately 2 molar equivalents of hydrochloric acid. CHN analysis:<!-- EPO <DP n="13"> --> theoretical (correcting 4.9 wt% water) C 47.89%, H 5.37%, N 3.72%, Na 12.22%; actual C 47.69%, H 5.23%, N 3.45%, Na 11.79%.</p><heading id="h0010"><u>Example 3</u></heading><heading id="h0011"><u>Preparation of Monosodium <i>N</i>-(5-chlorosalicyloyl)-8-aminocaprylate</u></heading><p id="p0032" num="0032">A 22 L, Pyrex glass, five-neck, round bottom flask was equipped with an overhead stirrer, thermocouple temperature read out, and heating mantle. The flask was charged with 2099.7 g of <i>N</i>-(5-chlorosalicyloyl)-8-aminooctanoic acid and 6000 mL water and stirred. To this slurry was added a solution of 265 g of sodium hydroxide dissolved in 2000 mL water. The mixture was heated to about 80° C causing most of the solids to dissolve. The undissolved material was allowed to settle to the bottom of the flask and the supernate decanted. The resulting mixture was transferred to the pot flask of a large laboratory rotary evaporator. The rotary evaporator was operated with a bath temperature of about 60° C and a pressure of about 70 mmHg. Water was removed from the disodium salt mixture until a solid mass was obtained in the rotary evaporator pot flask. The vacuum was released and pot flask removed from the rotary evaporator. The solids were scraped from the pot flask into trays. These trays were then placed in a vacuum oven and the solids dried at about 60° C and full vacuum for about 48 hours. The dried solids were run through a laboratory mill until all the solids passed through a 35 mesh screen. The milled and seived disodium N-(5-chlorosalicyloyl)-8-aminooctanate was put into trays and placed back into the drying oven. Drying was continued at full vacuum to yield 2161.7 g of the desired product as a dry powder.</p><p id="p0033" num="0033">Titration of the product with hydrochloric acid gave a single inflection point consuming approximately 1 molar equivalent of hydrochloric acid. CHN analysis: theoretical (correcting 1.14 wt% water) C 53.05%, H 5.77%, N 4.12%, Na 6.77%; actual C 52.57%, H 5.56%, N 4.06%, Na 6.50%.</p><heading id="h0012"><u>Example 4</u></heading><p id="p0034" num="0034">Disodium and monosodium salts of 5-CNAC were dosed to Rhesus monkeys as follows. Six monkeys in one group were each dosed with one capsule containing the disodium salt, while six monkeys in a second group were each dosed with one capsule containing the monosodium salt. Each capsule was prepared by hand-packing 400 mg 5-CNAC<!-- EPO <DP n="14"> --> (mono- or di- sodium salt) and 800 µg salmon calcitonin (sCT) into a hard gelatin capsule.</p><p id="p0035" num="0035">The Rhesus monkeys were fasted overnight prior to dosing and were restrained in chairs, fully conscious, for the duration of the study period. The capsules were administered via a gavage tube followed by 10 ml water.</p><p id="p0036" num="0036">Blood samples were collected at 15, 30, and 45 minutes and at 1, 1.5, 2, 3, 4, 5, and 6 hours after administration. Plasma concentration sCT was determined by radio-immunoassay. The results from the six monkeys in each dosing group were averaged for each time point and plotted. The maximum mean plasma calcitonin concentration and the area under the curve (AUC) are reported below in Table 1.
<tables id="tabl0001" num="0001"><table frame="all"><title><u>Table 1</u></title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="42mm"/><colspec colnum="2" colname="col2" colwidth="41mm"/><colspec colnum="3" colname="col3" colwidth="27mm"/><colspec colnum="4" colname="col4" colwidth="43mm"/><colspec colnum="5" colname="col5" colwidth="14mm"/><thead><row><entry align="center" valign="top">Delivery Agent</entry><entry align="center" valign="top">Delivery Agent Dose (mg)</entry><entry align="center" valign="top">sCT Dose (mg)</entry><entry align="center" valign="top">Mean Peak Plasma Calcitonin Concentration (pg/ml ± Standard Deviation) (Standard Error)</entry><entry align="center" valign="top">AUC</entry></row></thead><tbody><row><entry>Disodium salt of 5-CNAC</entry><entry align="center">400</entry><entry align="center">800</entry><entry align="center">424 ± 230 (94)</entry><entry align="center">883</entry></row><row><entry>Monosodium salt of 5-CNAC</entry><entry align="center">400</entry><entry align="center">800</entry><entry align="center">93.2 ± 133 (54)</entry><entry align="center">161</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="15"> --></p><heading id="h0013"><u>Example 7</u></heading><heading id="h0014"><u>Preparation of Disodium <i>N</i>-(5-chlorosalicyloyl)-8-aminocaprylate Ethanol Solvate</u></heading><p id="p0037" num="0037"><chemistry id="chem0002" num="0002"><img id="ib0002" file="imgb0002.tif" wi="161" he="59" img-content="chem" img-format="tif"/></chemistry></p><p id="p0038" num="0038">A 12 L, Pyrex glass, four-neck, round bottom flask was equipped with an overhead stirrer, thermocouple temperature read out, reflux condenser, and heating mantle. The flask was purged with dry nitrogen and the following reaction was conducted under an atmosphere of dry nitrogen. The flask was charged with 1000 g of <i>N</i>-(5-chloro-salicyloyl)-8-aminooctanic acid and 3000 mL of absolute ethanol. This slurry was heated to 55° C with stirring to obtain a slightly hazy solution. The reactor was then charged with 2276 g of 11.2 wt% sodium hydroxide dissolved in absolute ethanol as rapidly as possible. There was a slight exothermic reaction causing the temperature in the reactor to rise to about 64° C and a precipitate began to form. The reflux condenser was removed and the reactor set for distillation. The reaction mixture was distilled over the next three hours to obtain about 2566 g of distillate. The pot slurry was allowed to cool slowly to room temperature. The product solids in the slurry were recovered by vacuum filtration through a sintered glass funnel to obtain 1390 g of ethanol wet cake. The wet cake was transferred to glass trays and placed in a vacuum oven. The cake was dried to constant weight at about 45° C and full vacuum. The dry product had a weight of about 1094.7 g.</p><p id="p0039" num="0039">Titration of the product with hydrochloric acid gave two inflection points consuming approximately 2 molar equivalents of hydrochloric acid. CHN analysis: theoretical (correcting 0 wt% water) C 50.56%, H 5.99%, N 3.47%, Na 11.39%; actual C 50.24%, H 5.74%, N 3.50% (Na was not measured).<!-- EPO <DP n="16"> --></p><heading id="h0015"><u>Example 18</u></heading><heading id="h0016"><u>Preparation of <i>N</i>-(5-chlorosalicyloy)-8-aminocaprylic acid (5-CNAC)</u></heading><p id="p0040" num="0040">5-chlorosaticylamide (280 g, 1.6 mol) and acetonitrile (670 ml) were placed in a 5 liter, 4-neck, round bottomed, flask under a nitrogen atmosphere and stirred. Pyridine (161.3 g, 2.0 mol) was added over a period of 25 minutes to the mixture. The reaction vessel was placed in an ice/water bath and portionwise addition of ethyl chloroformate was started. This addition continued over a period of one hour. When the addition was completed the ice/water bath was removed and the reaction mixture was allowed to come to room temperature. The reaction mixture was allowed to stir for an additional one hour at room temperature before the reaction vessel was reconfigured for distillation at atmospheric pressure. The distillation that followed yielded 257.2 g of distillate at a head temperature of 78° C. 500 ml of deionized water was added to the reaction mixture that remained in the flask and the resulting slurry was vacuum filtered. The filter cake was washed with 200 ml deionized water and was allowed to dry overnight <i>in vacuo</i> at room temperature. 313.6 g (97.3%) of 6-chloro carsalam was isolated after drying. An additional batch was made using this same method, yielding 44.5 g 6-chloro-2H-1,3-benzoxazine-2,4(3H)-dione.</p><p id="p0041" num="0041">Sodium carbonate (194.0g, 1.8 mol) was added to a 5 liter, 4-neck, round bottomed, flask containing 6-chloro-2H-1,3-benzoxazine-2,4(3H)-dione (323.1 g, 1.6 mol) and dimethylacetamide (970 ml). Ethyl-8-bromooctanoate (459.0 g, 1.8 mol) was added in one portion to the stirring reaction mixture. The atmospheric pressure in the reaction vessel was reduced to 550 mm Hg and heating of the reaction mixture was started. The reaction temperature was maintained at 70° C for approximately 5 hours before heating and vacuum were discontinued. The reaction mixture was allowed to cool to room temperature overnight. The reaction mixture was vacuum filtered and the filter cake was washed with ethyl alcohol<!-- EPO <DP n="17"> --> (525 ml). Deionized water(525 ml) was slowly added to the stirred filtrate and a white solid precipitated. An ice/water bath was placed around the reaction vessel and the slurry was cooled to 5° C. After stirring at this temperature for approximately 15 minutes the solids were recovered by vacuum filtration and the filtercake was washed first with ethanol (300 ml) and then with heptane (400 ml). After drying overnight at room temperature <i>in vacuo,</i> 598.4 g (99.5%) of ethyl 8-(6-chloro-2H-1,3-benzoxazine-2,4(3H)-dionyl)octanoate was obtained. An additional 66.6 g of ethyl 8-(6-chloro-2H-1,3-benzoxazine-2,4(3H)-dionyl)octanoate was made by this same method.</p><p id="p0042" num="0042">Ethyl 8-(6-chloro-2H-1,3-benzoxazine-2,4(3H)-dionyl)octanoate (641 g, 1.7 mol) and ethyl alcohol (3200 ml) were added to a 22 liter, five neck flask. In a separate 5 liter flask, sodium hydroxide (NaOH) (288.5 g, 7.2 mol) was dissolved in deionized water (3850 ml). This mixture was added to the reaction mixture contained in the 22 liter flask. A temperature increase to 40° C was noted. Heating of the reaction mixture was started and when the reaction temperature had increased to 50° C it was noted that all of the solids in the reaction mixture had dissolved. A temperature of 50° C was maintained in the reaction mixture for a period of 1.5 hours. The reaction flask was then set up for vacuum distillation. 2200 ml of distillate were collected at a vapor temperature of 55° C (10 mm Hg) before the distillation was discontinued. The reaction flask was then placed in an ice/water bath and concentrated hydrochloric acid (HCl) (752 ml) was added over a period of 45 minutes. During this addition the reaction mixture was noted to have thickened somewhat and an additional 4 liters of deionized water was added to aid the stirring of the reaction mixture. The reaction mixture was then vacuum filtered and the filter cake was washed with 3 liters of deionized water. After drying <i>in vacuo</i> at room temperature 456.7 g (83.5%) of N-(5-chlorosalicyloyl)-8-aminocaprylic acid was isolated.<!-- EPO <DP n="18"> --></p><heading id="h0017"><u>Example 26</u></heading><heading id="h0018">Preparation of 5-CNAC for Tableting</heading><p id="p0043" num="0043">To a clean, dry, 757,1ℓ (200 gallon) glass-lined reactor, 178 L of dry acetonitrile was added. The agitator was set to 100-125 RPM and the reactor contents were cooled to 9° C. 74 kg of 5-chloro salicylamide, available from Polycarbon Industries of Leominster, MA, was charged to the reactor and the charging port was closed. 47 L of dry pyridine was charged to the reactor. The slurry was cooled to 9° C prior to proceeding. Cooling was applied to the reactor condenser and valve overheads were set for total reflux. Over 2 hours, 49.7 kg of ethylchloroformate was charged to the 757,1ℓ (200 gallon) reactor while maintaining the batch temperature at 14° C. Note that ethylchloroformate can contain 0.1% phosgene and is extremely reactive with water. The reacton is highly exothermic and requires the use of a process chiller to moderate reaction temperature. The reactor contents were agitated for 30<!-- EPO <DP n="19"> --> minutes at 10-14° C once the ethylchloroformate addition was complete. The reactor contents were heated to 85° C over 25 minutes, collecting all distillate into a receiver. The reactor contents were held at 85.94° C for approximately 6 hours, collecting all distilled material into a receiver. The reaction mixture was sampled and the conversion (&gt;90%) monitored by HPLC. The conversion was found to be 99.9% after 6 hours. The reactor contents were cooled to 19° Cover a one-hour period. 134 Lofdeionized water was charged to the reactor. A precipitate formed immediately. The reactor contents were cooled to 5° C and agitated for 10.5 hours. The product continued to crystallize out of solution. The reactor slurry was centrifuged. 55 L of deionized water was charged to the 757,1ℓ (200-gallon), glass-lined reactor and the centrifuge wet cake was washed. The intermediate was dried under full vacuum 948.2 HPa (28" Hg) and 58° C for 19.5 hours. The yield was 82.6 kg 6-chloro-2H-1,3-benzoxazine-2,4(3H)-dione. This intermediate was packaged and stored so that it was not exposed to water.</p><p id="p0044" num="0044">In the next preparation, absolutely no water can be tolerated in the steps up to the point where distilled water is added.</p><p id="p0045" num="0045">222 L of dry dimethylacetamide was charged to a dry 757,1ℓ (200 gallon) glass-lined reactor. The reactor agitator was set to 100-125 RPM. Cooling was applied to the condenser and valve reactor overheads were set for distillation. 41.6 kg of dry anhydrous sodium carbonate was charged to the reactor and the reactor charging port was closed. Caution was used due to some off-gassing and a slight exotherm. 77.5 kg of dry 6-chloro-2H-1,3-benzoxazine-2,4(3H)-dione was charged to the reactor. Quickly, 88 kg of dry ethyl-8-bromooctanoate was charged to the reactor. 745.0-812.7 HPa (22-24 inches) of vacuum was applied and the reactor temperature was raised to 65-75 ° C. The reactor temperature was maintained and the contents were watched for foaming. The reactor mixture was sampled and monitored for conversion by monitoring for the disappearance of the bromo ester in the reaction mixture by gas chromatography (GC). The reaction was complete (0.6% bromo ester was found) after 7 hours. The vacuum was broken and the reactor contents cooled to 45-50° C. The contents were centrifuged and the filtrate sent into a second 757,1ℓ (200-gallon) glass-lined reactor. 119 L of ethanol (200 proof denatured with 0.5% toluene) was charged to the first 757,1ℓ (200-gallon) reactor, warmed to 45° C and the filter cake washed with warm ethanol, adding to the reaction mixture in the second 757,1ℓ (200-gallon) reactor. The agitator was started on the second 757,1ℓ (200-gallon) reactor. The reactor contents were cooled to 29° C. 120 L of distilled water was slowly charged to the second reactor, with the water falling directly into the batch. The reactor<!-- EPO <DP n="20"> --> contents were cooled to 8° C. The intermediate came out of solution and was held for 9.5 hours. The resultant slurry was centrifuged. 70 L of ethanol was charged to the reactor, cooled to 8° C and the centrifuge cake was washed. The wet cake was unloaded into double polyethylene bags placed inside a paper lined drum. The yield was 123.5 kg of ethyl S-(6-chloro-2H-1,3-benzoxazine-2,4(3H)-dionyl)octanoate.</p><p id="p0046" num="0046">400 L of purified water, USP and 45.4 kg NaOH pellets were charged to a 757,1ℓ (200 gallon) glass-lined reactor and the agitator was set to 100-125 RPM. 123.5 kg of the ethyl 8-(6-chloro-2H-1,3-benzoxazine-2,4(3H)-dionyl)octanoate wet cake was charged to the reactor. The charging port was closed. Cooling water applied to the condenser and the valve reactor overheads were set for atmospheric distillation. The reactor contents were heated to 98° C and conversion monitored by HPLC. Initially (approximately 40 minutes) the reactor refluxed at 68° C, however, as the ethanol was removed (over 3 hours) by distillation the reactor temperature rose to 98° C. The starting material disappeared, as determined by HPLC, at approximately 4 hours. The reactor contents were cooled to 27° C. 150 L of purified water and USP were charged to an adjacent 757,1ℓ (200 gallon) glass-lined reactor and the agitator was set to 100-125 RPM. 104 L of concentrated (12M) hydrochloric acid was charged to the reactor and cooled to 24° C. The saponified reaction mixture was slowly (over 5 hours) charged to the 200-gallon glass-lined reactor. The material (45 L and 45 L) was split into 2 reactors 757,1ℓ (200 gallons) each because of carbon dioxide evolution. The product precipitated out of solution. The reaction mixture was adjusted to a pH of 2.0-4.0 with 50% NaOH solution (2L water, 2 kg NaOH). The reactor contents were cooled to 9-15° C. The intermediate crystallized out of solution over approximately 9, hours. The reactor slurry was centrifuged to isolate the intermediate. 50 L of purified water and USP were charged to a 757,1ℓ (200-gallon) glass-lined reactor and this rinse was used to wash the centrifuge wet cake. The wet cake was unloaded into double polyethylene bags placed inside a plastic drum. The N-(5-chlorosalicyloyl)-8-aminocaprylic acid was dried under vacuum 914.3 HPa (27" Hg) at 68° C for 38 hours. The dry cake was unloaded into double polyethylene bags placed inside a 208,2ℓ (55-gallon), steel unlined, open-head drums with a desiccant bag placed on top. The dried isolated yield was 81 kg of <i>N</i>-(5-chlorosalicyloyl)-8-aminocaprylic acid.<!-- EPO <DP n="21"> --></p><heading id="h0019"><u>Example 30</u></heading><heading id="h0020"><u>Preparation of 5-CNAC</u></heading><p id="p0047" num="0047">5-CNAC was made under similar conditions as in Example 26 in a laboratory environment.</p></description><claims mxw-id="PCLM56987489" lang="DE" load-source="patent-office"><!-- EPO <DP n="23"> --><claim id="c-de-01-0001" num="0001"><claim-text>Verwendung einer Zusammensetzung umfassend
<claim-text>(a) N-(5-Chlorsalicyloyl)-8-aminocaprylsäure, wobei die Säure wenigstens 96 Gew.-% des Dinatriumsalzes von N-(5-Chlorsalicyloyl)-8-aminocaprylsäure umfasst;<br/>
und</claim-text>
<claim-text>(b) Lachs-Calcitonin, für die Herstellung einer Dosierungseinheitsform zum oralen Verabreichen von Lachs-Calcitonin an ein Lebewesen.</claim-text></claim-text></claim></claims><claims mxw-id="PCLM56987490" lang="EN" load-source="patent-office"><!-- EPO <DP n="22"> --><claim id="c-en-01-0001" num="0001"><claim-text>Use of a composition comprising
<claim-text>(a) N-(5-chlorosalicyloyl)-8-aminocaprylic acid, wherein said acid comprises at least 96% by weight of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid; and</claim-text>
<claim-text>(b) Salmon calcitonin, for the preparation of a dosage unit form for orally administering salmon calcitonin to an animal.</claim-text></claim-text></claim></claims><claims mxw-id="PCLM56987491" lang="FR" load-source="patent-office"><!-- EPO <DP n="24"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Utilisation d'une composition comprenant:
<claim-text>(a) de l'acide N-(5-chlorosalicyloyle)-8-aminocaprylique, où ledit acide comprend au moins 96% en poids du sel de disodium d'acide N-(5-chlorosalicyloyle)-8-aminocaprylique;<br/>
et</claim-text>
<claim-text>(b) de la calcitonine de saumon, pour l'élaboration d'une forme d'unité de dosage pour administration orale de calcitonine de saumon chez un animal.</claim-text></claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
